Before We Start
Not caught — unleashed
Most infections involve catching an organism from outside the body. Candida is different: it's already there, kept in check by competing bacteria, an intact immune system, and normal glucose regulation. Disease happens when one of those checks fails.
💡 Memory Trick
Candida: normal flora that overgrows when defenses drop — thrush, diaper rash, or systemic if immunocompromised. The organism doesn't change; what changes is which defense broke down.
The Key Points
Three presentations, each reflecting a different broken defense
C
Candida albicans — opportunistic, not exogenous
Candida albicans already lives in you as normal flora — in the mouth, GI tract, and vaginal tract. It only causes disease when something disrupts the normal balance: antibiotics wiping out competing bacteria, immunosuppression, or diabetes. On microscopy, it shows pseudohyphae — a key identifying feature.
🦠 The organism itself never changes between a harmless colonizer and an active infection — what changes is whether the surrounding checks (competing bacteria, immune function, glucose control) are still holding it back.
OT
Oral thrush — white plaques when local defenses drop
When Candida overgrows in the mouth, it produces oral thrush: white plaques on the tongue and oral mucosa. This is common in infants, denture wearers, inhaled corticosteroid users (asthma patients), and immunocompromised patients — populations where local oral defenses are weakened for different specific reasons.
🦠 An asthma patient using inhaled corticosteroids developing white oral plaques reflects the local immunosuppressive effect of the inhaled steroid on the oral mucosa specifically.
VV
Vulvovaginal candidiasis — cottage cheese discharge after antibiotic disruption
In the vaginal tract, Candida overgrowth produces a thick, white, cottage-cheese-like discharge along with intense itching (pruritus) — classically triggered by antibiotic use (which kills the competing lactobacilli), pregnancy, or diabetes.
🦠 A patient developing vulvovaginal candidiasis shortly after finishing a course of antibiotics reflects the loss of competing lactobacilli, which normally keep Candida overgrowth in check.
IC
Invasive candidemia — the dangerous, systemic form
In ICU patients — especially those with central venous lines, on broad-spectrum antibiotics, receiving TPN (total parenteral nutrition), or otherwise immunosuppressed — Candida can enter the bloodstream and cause invasive candidemia, a serious systemic infection. Treatment escalates with severity: fluconazole for mild-to-moderate disease, but an echinocandin for invasive or azole-resistant infections.
🦠 A patient in the ICU with a central line, on broad-spectrum antibiotics for a week, develops a new fever and blood cultures grow Candida — this is invasive candidemia, treated with an echinocandin rather than fluconazole given the severity and resistance risk.
🏥 Applied Scenario
A patient in the ICU has had a central venous line in place for over a week and has been on broad-spectrum antibiotics the entire time, then develops a new fever, with blood cultures growing Candida albicans.
Step 1
Explain why this happened: The central line, broad-spectrum antibiotics, and ICU setting are exactly the risk factors that let normally-harmless Candida invade the bloodstream — this is invasive candidemia, not a new exposure to a foreign organism.
Step 2
Determine appropriate treatment: Given the severity of invasive disease, treatment escalates beyond fluconazole to an echinocandin — reflecting the general principle that Candida treatment intensity should match how deep and dangerous the infection has become.
Step 3
Recognize the underlying lesson: The organism causing this bloodstream infection is the exact same species that likely already lived harmlessly in this patient's GI tract before the central line and antibiotics disrupted the normal balance.
Step 4
Conclusion: Candidemia in this setting isn't a new infection acquired from an outside source — it's the patient's own normal flora finding a route into the bloodstream once enough defenses had been compromised simultaneously.
📌 Exam Application
Exams test recognizing Candida's different clinical presentations by host context — oral thrush in infants/inhaled steroid users, vulvovaginal candidiasis after antibiotics, and invasive candidemia in ICU/immunosuppressed patients — and matching severity to the right antifungal (fluconazole for mild-moderate, echinocandin for invasive/resistant disease).
⚠️ The Trap — Treating Candida as an Exogenous Infection
The most common trap is thinking of Candida as something a patient catches from an outside source, the way you would with most infections. It's normal flora that overgrows when the immune system, competing bacteria, or metabolic regulation weakens — the organism was already there, and the real question is always which defense broke down, not where the organism came from.
✓ Quick Self-Test
Answer before checking:
1. Why is Candida albicans called an opportunistic pathogen rather than an exogenous one?
2. What does Candida look like on microscopy?
3. What are the classic triggers for vulvovaginal candidiasis?
4. What patient population is at highest risk for invasive candidemia, and why?
5. How does antifungal treatment change between mild and invasive Candida infections?
Answers:
1. Because it's already normal flora living in the mouth, GI tract, and vagina; it only causes disease when normal defenses (immune system, competing bacteria, glucose control) are disrupted.
2. Pseudohyphae.
3. Antibiotic use, pregnancy, and diabetes.
4. ICU patients with central venous lines, broad-spectrum antibiotic use, TPN, or immunosuppression — these disrupt normal flora balance and provide a route into the bloodstream.
5. Fluconazole treats mild-to-moderate disease; invasive or azole-resistant candidemia requires an echinocandin.